Background: Leishmaniasis is a complex protozoa disease caused by
Leishmania genus (Trypanosomatidae family). Currently, there have been renewed interests worldwide in plants as pharmaceutical agents. In this study, the
in vivo efficacy of
Solanum spp. is assessed in an
L. amazonensis BALB/c mice
[...] Read more.
Background: Leishmaniasis is a complex protozoa disease caused by
Leishmania genus (Trypanosomatidae family). Currently, there have been renewed interests worldwide in plants as pharmaceutical agents. In this study, the
in vivo efficacy of
Solanum spp. is assessed in an
L. amazonensis BALB/c mice model for experimental cutaneous leishmaniasis.
Methods: Animals were infected with 5 × 10
6 metacyclic promastigotes and 30-day post-infection, a treatment with 30 mg/kg of
Solanum extracts or Glucantime
® (GTM) was applied intralesionally every four days to complete 5 doses.
Results: Neither death nor loss of weight higher than 10% was observed. All the tested extracts were able to control the infection, compared with the infected and untreated group.
Solanum havanense Jacq. extract showed the highest efficacy and was superior (
p < 0.05) to GTM.
Solanum myriacanthum Dunal.,
S. nudum Dunal. and
S. seaforthianum Andr. extracts demonstrated a similar effect (
p > 0.05) to GTM. An increase of IFN-γ (
p < 0.05) was displayed only by animals treated with
S. nudum compared to the group treated with a vehicle, while no differences (
p > 0.05) were observed for IL-12.
Conclusions: In vivo effects of
Solanum extracts were demonstrated, suggesting that this genus could be further explored as a new antileishmanial alternative.
Full article
